What is the treatment for herpes zoster (shingles) in the eye?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Shingles in the Eye (Herpes Zoster Ophthalmicus)

Start oral valacyclovir 1000 mg three times daily for 7 days immediately upon diagnosis, and arrange urgent ophthalmology referral within 24 hours while continuing antiviral therapy. 1, 2

Immediate Antiviral Therapy

First-line treatment is oral valacyclovir 1000 mg three times daily for 7 days, which is preferred due to superior bioavailability and simpler dosing compared to acyclovir. 1, 2, 3 The American Academy of Ophthalmology recommends starting antivirals immediately—do not delay treatment while waiting for ophthalmology consultation. 2

Alternative oral antiviral regimens include:

  • Acyclovir 800 mg five times daily for 7 days 1, 2, 4
  • Famciclovir 500 mg three times daily for 7 days 1, 2

Treatment is most effective when initiated within 72 hours of rash onset, though evidence suggests valacyclovir may still provide benefit when started later than 72 hours. 1, 5 Adjust dosing for renal impairment—exercise caution in patients with reduced creatinine clearance. 1, 3

Mandatory Ophthalmology Involvement

All cases of facial shingles near or involving the eye require immediate involvement of an experienced ophthalmologist. 2 Herpes zoster ophthalmicus can cause serious vision-threatening complications including:

  • Pseudodendrites and keratitis 1, 2
  • Corneal scarring and vascularization 1, 2
  • Iritis/uveitis and sectoral iris atrophy 1, 2
  • Secondary glaucoma 1, 2
  • Neurotrophic keratitis from corneal anesthesia 1, 2

Adjunctive Topical Therapy

Apply topical antibiotics to vesicles to prevent secondary bacterial infection, which can lead to severe complications including cicatricial ectropion. 1, 2 This has high-strength evidence supporting its use. 1

Avoid topical corticosteroids during active epithelial viral infection as they can potentiate the infection. 1, 2 However, for inflammatory complications without epithelial disease (such as subepithelial infiltrates causing blurred vision and photophobia), topical corticosteroids at the minimum effective dose may be considered under ophthalmologist supervision only. 1, 2

Topical antivirals alone are not helpful for VZV conjunctivitis and should not be used as monotherapy, as they do not reach the site of viral reactivation in the ganglia. 1, 2 Ganciclovir 0.15% gel or trifluridine 1% solution may be used as additive treatment in unresponsive patients. 1, 2

Special Populations

Immunocompromised patients require more aggressive antiviral therapy with potential dose adjustments based on clinical response. 1, 2 High-dose IV acyclovir remains the treatment of choice for VZV infections in severely compromised hosts. 2 Patients with chronic or recalcitrant disease may require prolonged treatment beyond the standard 7-day course. 1, 2

Follow-Up Protocol

Schedule follow-up within 1 week of treatment initiation, including: 1, 2

  • Interval history 1, 2
  • Visual acuity measurement 1, 2
  • Slit-lamp biomicroscopy 1, 2
  • Assessment for resolution of acute symptoms 2
  • Evaluation for development of complications 2
  • Intraocular pressure measurement if on corticosteroid therapy 1, 2

Critical Pitfalls to Avoid

Do not delay antiviral treatment waiting for ophthalmology consultation—start oral antivirals immediately while arranging urgent referral. 2 The window for maximum antiviral efficacy is narrow. 1

Monitor for late sequelae including dry eye and neurotrophic keratitis, which may develop months after the acute infection and require ongoing monitoring. 1, 2 These complications can occur despite appropriate acute treatment. 1

Never use topical antivirals as monotherapy, as they are ineffective for treating the underlying ganglionic viral reactivation. 2

References

Guideline

Treatment for Periorbital Cellulitis Linked to Herpes Zoster Ophthalmicus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Shingles of the Face

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.